期刊文献+

侵袭性垂体腺瘤治疗和预后影响因素分析 被引量:20

Invasive pituitary adenomas: clinical outcome and treatment strategies
原文传递
导出
摘要 目的探讨侵袭性垂体腺瘤的手术疗效及治疗策略。方法回顾性分析武汉同济医院神经外科垂体瘤组37例海绵窦侵袭性垂体腺瘤的临床疗效。结果37例均行手术治疗,其中经鼻蝶27例,分期经鼻蝶2例,经颅4例,联合人路4例。全切除11例,次全切除14例,部分切除12例。术后症状改善28例,缓解5例,未愈4例。术后辅助治疗11例。随访5~51个月,中位时间25个月,复发13例,复发率35%,复发患者平均无复发生存时间35.8个月。肿瘤切除程度,术后是否予以辅助治疗以及是否有肿瘤包绕颈内动脉与预后明显相关。结论侵袭性垂体腺瘤采取以手术为主的综合治疗策略,经鼻蝶入路可以成为侵袭性垂体腺瘤手术治疗的首选方式,术后辅助治疗能够延长无复发生存时间。 Objective To analyze the clinical characteristics of invasive pituitary adenomas, and discuss the clinical outcome and therapeutic strategies. Methods To summarize clinical characteristics and therapeutic effect of invasive pituitary tumor involving cavernous sinus through studying 37 cases who had the full MR imaging findings, endocrinology and pathology data and follow - up information retrospectively. Results Among the 37 patients, 27 cases were underwent trans -sphenoid surgery, 2 staged trans - sphenoid surgery, 4 trans - sphenoid combined with transcranial operation and 4 transcranial surgery. 11 patients had achieved gross total resection, 14 subtotal resection, 12 partial resection. 11 cases received post -operation adjunctive therapy; 28 patients improved, 5 alleviated and 4 unrecovered. Recurrence during the follow up occurred in 13 patients (35%). The average recurrence -free survival was 35.8 months for a median follow - up of 25 months. Recurrence was associated with the degree of tumor resection, post - operation adjunctive therapy and encasing the internal carotid arteries. Conclusions Aggressive pituitary adenomas should be taken multimodality therapy: trans -sphenoidal surgery should be the first choice postoperative adjunctive therapy can improve the clinical outcome and prolong recurrence -free survival.
出处 《中华神经外科杂志》 CSCD 北大核心 2013年第5期451-455,共5页 Chinese Journal of Neurosurgery
基金 国家自然科学基金(30672161)
关键词 垂体腺瘤 侵袭性 外科手术 治疗 Pituitary adenmoma Invasive Surgery Treatment
  • 相关文献

参考文献23

  • 1Zhao B, Wei YK, Li GL, et al. Extended transsphenoidal appr-oach for pituitary adenomas invading the anterior cranial base,cavernous sinus, and clivus : a single-center experience with 126consecutive cases. J Neurosurg, 2010,112: 108-117.
  • 2Mortini P, Barzaghi R, Losa M, et al. Surgical treatment of giantpituitary adenomas : strategies and results in a series of 95consecutive patients. Neurosurgery, 2007, 60: 993-1002 ;discussion 1003-1004.
  • 3张荣,周良辅.侵袭性垂体瘤的诊断和治疗[J].临床外科杂志,2004,12(4):201-202. 被引量:13
  • 4任祖渊,杨义,苏长保,王任直,陶蔚,马文斌,李永宁.垂体腺瘤侵袭性与海绵窦颈内动脉的关系和手术疗效[J].中国医学科学院学报,2005,27(1):13-17. 被引量:6
  • 5Buchfelder M. Management of aggressive pituitary adenomas: cu-rrent treatment strategies. Pituitary, 2009 , 12 : 256-260.
  • 6Homyak M,Couldwell WT. Multimodality treatment for invasi-vepituitary adenomas. Postgrad Med, 2009 , 121 : 168-176.
  • 7Colao A, Grasso LF, Pivonello R, et al. Therapy of aggressivepituitary tumors. Expert Opin Pharmacother, 2011, 12:1561-1570.
  • 8Buchfelder M. Treatment of pituitary tumors: surgery. Endoc-rine, 2005, 28: 67-75.
  • 9Primeau V, Raftopoulos C, Maker D. Outcomes of transsph-enoidal surgery in prolactinomas : improvement of hormonalcontrol in dopamine agonist-resistant patients. Eur J Endocrinol,2012,166: 779-786.
  • 10Colao A, Attanasio R, Pivonello R,et al. Partial surgical removalof growth hormone-secreting pituitary tumors enhances theresponse to somatostatin analogs in acromegaly. J Clin EndocrinolMetab, 2006,91 : 85-92.

二级参考文献26

  • 1[1]Thapar K, Kovacs K, Sehelthauer BW, et al. Proliferative activity and invasiveness mnong pituitary adeenonas and carcinomas: analysis using the MIB-l antibody[J]. J Neurosurg, 1996, 38:99-107
  • 2[2]Kawamoto H, Daly MA, Mililan I, et al. Type IV collagenase activity and cavernous sinus invasion in the hunman pituitary adenoma [ J ]. Acta Neurochir, 1996, 138(4):390-340
  • 3[3]Yildiz F, Zorlu F, Erbas T, et al. Radiotherapy in the management of giant pituitary adenomas[J]. Radiother Oncol, 1999, 52:233-237
  • 4[4]Jho HD, Carraiu RL, Ko Y, et al. Endoscopic pituitary surgery: an early experience[J]. Surg Neurol, 1999, 47:213-222
  • 5[5]Basaria S, Turchin A, Krasner A. Apoplexy in recurrent pituitaryadenomas[J]. Postgrad Med J, 2001, 77:23-26
  • 6[6]Tan EU, Ho MS, Rjasoorya Cr. Metanororphosis of non-functioning pituitary adenonta to Cushing's disease[J]. Pituitary, 2000, 3:117-122
  • 7[7]Machiavelli GA, Yoshimoto T, Schiwa T. Expression of c-myc and binding site: estradial and progesterone in hunan pituitary tumor[J]. Neurol Res,1998, 20:709-712
  • 8[8]Shimom I, Pinget M, Kessler 1. Prolactinomas express human heparinbinding secretory transformation gene (hst) protein product: marker oftumor invasiveness[J]. Clin Endocrinol Oxf, 1998, 48:23
  • 9[9]Thapar K, Schirna W, Atahaan L, et al. p53 expression in pituitarryadenoma and carcinonms: correlation with invasiveness and tumor growthfraction[J]. Neurosurgery, 1996, 38:763-769
  • 10[10]Dickstein G. Late complication in remission from Cushing disease[J].Arch Intern Med, 1997, 10:157-161

共引文献46

同被引文献133

引证文献20

二级引证文献73

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部